Vestmark Advisory Solutions Inc. Purchases 25,300 Shares of Natera, Inc. $NTRA

Vestmark Advisory Solutions Inc. lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 104.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,636 shares of the medical research company’s stock after acquiring an additional 25,300 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Natera were worth $8,386,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares during the period. Nuveen LLC bought a new position in shares of Natera in the 1st quarter valued at about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Natera by 140.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock worth $177,298,000 after buying an additional 732,156 shares during the period. JPMorgan Chase & Co. grew its position in shares of Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock worth $1,041,055,000 after buying an additional 660,538 shares during the period. Finally, Ninety One UK Ltd raised its stake in shares of Natera by 149.1% during the second quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company’s stock worth $95,111,000 after buying an additional 336,985 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of Natera stock opened at $199.57 on Friday. The company has a market capitalization of $27.39 billion, a P/E ratio of -87.15 and a beta of 1.75. The business has a 50-day moving average of $177.75 and a two-hundred day moving average of $163.67. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $203.23.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, November 6th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.20%. The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. Natera’s revenue for the quarter was up 34.7% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Activity at Natera

In related news, CFO Michael Burkes Brophy sold 1,867 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $190.64, for a total value of $355,924.88. Following the sale, the chief financial officer directly owned 64,126 shares of the company’s stock, valued at approximately $12,224,980.64. The trade was a 2.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00. Following the completion of the transaction, the insider directly owned 112,061 shares of the company’s stock, valued at approximately $22,255,314.60. The trade was a 2.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 224,889 shares of company stock worth $43,232,062 over the last three months. 5.63% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of recent research reports. Barclays raised their price objective on shares of Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Stephens reaffirmed an “overweight” rating and set a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. Canaccord Genuity Group increased their target price on Natera from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Friday. Finally, Evercore ISI raised their target price on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday. Seventeen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $206.74.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.